GE HealthCare

GE HealthCare Receives FDA Clearance for Photonova Spectra Photon-Counting CT Solution

Stryker

Stryker's CEO Joins GE HealthCare Board Amid Cyberattack Recovery and Digital Health Expansion

GE HealthCare: BTIG reiterates Buy, raises PT to $91 from $91.

GE HealthCare Completes Intelerad Acquisition to Accelerate Shift to Cloud-First Enterprise Solutions

GE HealthCare's 15min chart shows Bollinger Bands Narrowing, KDJ Death Cross.

Catalyst<ul> <li>Most analysts rate GEHC Buy or Strong Buy, showing broad institutional optimism.</li> <li>Recent Bullish Engulfing and WR Oversold signals in late November and early December point to rebound momentum for GEHC.</li></ul>Risk<ul> <li>Health-care companies fell amid regulatory fears as the Federal Trade Commission warned about consolidation and anticompetitive conduct in the industry.</li> <li>Small and medium-sized fund flows are showing negative trends indicating potential pressure from retail and mid-sized investors.</li></ul>

Key Factors

GE HealthCare receives FDA clearance for Photonova Spectra, a photon-counting CT solution utilizing Deep Silicon detector technology.

GEHC News